Cahn P, Coll P, Perez MS, Rolon M, Cando O, Votto L; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 4th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 4th 1997 Wash DC. 1997 Jan 22-26; 4th: 159 (abstract no. 514).
Htal Fernandez, Buenos Aires, Argentina.
OBJECTIVE: To evaluate ZDV efficacy and safety in prevention of HIV vertical transmission, starting on week 24. METHODS: Between 12/94 - 9/96, 105 pregnant woman were assisted. ZDV was given following CDC guidelines, but beginning treatment on the 24th week. Informed consent was obtained. Monthly differential blood counts, CD4 counts at entry and postpartum, were performed to mothers. HIV-1 tests were performed at birth and on a 6 month basis. Newborns CD4 were studied at 30, 180 and 365 days. Blood counts were studied at days 0 and 180. RESULTS: Among 80 eligible pts 58 (72.5%) received ZDV, the other 22 refused treatment Pretreatment median maternal CD4: 446/mm3 (180 - 1447), post-treatment 570 (150-1218). Median pretreatment maternal hemoglobin (Hb) 11.37 g/dl, post-treatment 12. Infant median CD4: 1860 (1281 - 3653), median Hb post ZDV 10.2. Neither discontinuation of treatment, nor transfussion were necessary in any case. A total of 81 newborns were assisted as of September 1th, 1996. Median follow-up: 5 months (1 -20). In the ZDV group 18 out of 59 newborns seroreverted (30.5%), in the non-treated group 1 out of 22 did so (4.5%) p is less than 0.04. The other 62 babies remain in stage "E" (41 in ZDV, 21 non-treated). CONCLUSIONS: Use of ZDV in pregnant and newborns was well tolerated in our population. Starting ZDV in week 24 seems to be effective and safe in reducing perinatal transmission. If the efficacy is similar to the standard protocol (starting week 14-34), a shorter treatment could be advantageous in terms of cost, toxicity and compliance. Updated data will be presented.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antigens, CD4
- Argentina
- Disease Transmission, Vertical
- Female
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Infant
- Infant, Newborn
- Parturition
- Pregnancy
- Zidovudine
- immunology
- prevention & control
- therapy
- transmission
Other ID:
UI: 102223569
From Meeting Abstracts